Betta Pharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 300558.SZ

Betta Pharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2023: USD 58.25 M

Betta Pharmaceuticals Co., Ltd. Goodwill is USD 58.25 M for the year ending December 31, 2023, a -2.80% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Betta Pharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2022 was USD 59.93 M, a -7.92% change year over year.
Betta Pharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2021 was USD 65.09 M, a 2.73% change year over year.
Betta Pharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2020 was USD 63.36 M, a 3.22% change year over year.
Betta Pharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2019 was USD 61.38 M, a 2.07% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Shenzhen Stock Exchange: 300558.SZ

Betta Pharmaceuticals Co., Ltd.

CEO	Dr. Lieming Ding
IPO Date	Nov. 9, 2016
Location	China
Headquarters	No. 355, Xingzhong Road
Employees	1,961
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Drugstores & Retail Pharmacies

Description

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.

Key trends

Past 5 years